LR Health & Beauty SE, Europe’s leading digital social commerce company in the area of high-quality health and beauty products, today published its figures for the second quarter of 2024 and the first half of 2024.
In the second quarter of financial year 2024,
LR Health & Beauty SE managed to increase sales (revenue from goods sold) by 2.6% to EUR 70.7 million (Q2 2023*: EUR 68.9 million).
In the first half of the year, LR Health & Beauty SE thus generated sales of EUR 143.3 million (H1 2023*: EUR 140.9 million).
New product launches, such as the LR Health Mission and the LR Body Mission, contributed significantly to the positive sales performance during the period.
LR Health & Beauty SE generated a normalized EBITDA of EUR 14.4 million in the first six months of financial year 2024, compared to EUR 17.5 million in the same period of the previous year*.
The earnings performance was impacted by factors such as refinancing costs related to the early redemption of the old bond of LR Global Holding GmbH and the issuance of a New Bond by LR Health & Beauty SE, as well as negative currency effects. EBITDA reported amounted to EUR 11.7 million in the first half